Literature DB >> 32591877

SARS-CoV-2-associated cold agglutinin disease: a report of two cases.

Tessa Huscenot1, Joris Galland1, Margot Ouvrat2, Mathias Rossignol2, Stéphane Mouly1, Damien Sène3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32591877      PMCID: PMC7317069          DOI: 10.1007/s00277-020-04129-9

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


× No keyword cloud information.
Dear Editor, Hematological manifestations reported in SARS-CoV-2 infection mainly include lymphocytopenia as a poor prognosis factor [1]. Thrombocytopenia can be associated with disseminated intravascular coagulation [2] or immune process [3]. Data regarding anemia are scarce and in line with a recent report on six patients with heterogeneous hemolytic anemia [4], we herein report on two patients with SARS-CoV-2-related cold agglutinin disease (CAD).

Patient 1

A 43-year-old woman was admitted after a 10-day course of asthenia, fever, cough, diarrhea, and dyspnea. Her medical history comprised obesity and untreated multiple sclerosis. Nasopharyngeal Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) confirmed SARS-CoV-2 infection. Chest computed tomography showed a typical severe interstitial pneumonia. Hemoglobin was normal upon admission (13.1 g/dL). A treatment with oxygen support and antibiotics (ceftriaxone and azithromycin for 3 days then tazocillin for 3 days) was started, with a rapid improvement of respiratory parameters. At day 6, hemoglobin levels dropped to 6.1 g/dL, with hemolytic features (low haptoglobin, elevated bilirubin, and lactate dehydrogenase (LDH) levels). The direct antiglobulin test (4+) was positive with the presence of cold agglutinins (Fig. 1). Etiological workup for hemolysis was negative. After poor initial transfusion efficiency, hemoglobin levels and hemolytic parameters improved.
Fig. 1

Evolution of the biological parameters of cold agglutinin-associated hemolysis. a Evolution of the biological parameters of hemolysis in patient 1; b evolution of the biological parameters of hemolysis in patient 2

Evolution of the biological parameters of cold agglutinin-associated hemolysis. a Evolution of the biological parameters of hemolysis in patient 1; b evolution of the biological parameters of hemolysis in patient 2

Patient 2

A 63-year-old man, with a medical history of hypertension, was admitted for severe acute respiratory syndrome in intensive care unit (ICU). In the last 2 weeks, he presented with fever, cough, and progressive worsening dyspnea. The nasopharyngeal RT-PCR confirmed a SARS-CoV-2 infection. The initial blood count showed a non-regenerative normocytic anemia (10.5 g/dL). As haptoglobin levels were unmeasurable (< 0.08 g/L), contrasting with increased serum orosomucoid (2.35 g/L), a hemolytic process was suspected and the direct antiglobulin test was positive (C3 [4+] and IgG [2+]) with cold agglutinins (Fig. 1). At day 6 of hospitalization, hemoglobin level decreased to 8.2 g/dL. Etiological workup was negative. Hemoglobin improved within 9 days along with clinical improvement. We here report two supplemental cases of SARS-CoV-2-associated autoimmune hemolytic anemia with cold agglutinins which seems to be a rare but nevertheless real complication of this condition. CAD was previously reported in association with viral infections and Mycoplasma pneumonia infection. The pathophysiological mechanism might be related to an antigen cross-reaction with red blood cell secondary to molecular mimicry, as with Influenzae disease [5]. A drug-induced CAD was considered uncommon [6]. We believe that a more extensive investigation of anemia in SARS-CoV2 patients, including the appraisal of hemolytic patterns might be useful for the detection of other cases of CAD and appropriate management of anemia during SARS-CoV2-infection.
  9 in total

1.  Positive direct antiglobulin tests in cancer patients hospitalized with COVID-19: A brief report from India.

Authors:  S S Datta; S Basu; D Basu; M Reddy; S Chatterji
Journal:  Transfus Clin Biol       Date:  2022-06-03       Impact factor: 2.126

2.  Severe Anemia Due to Cold Agglutinin Syndrome in a COVID-19 Patient with IgM Monoclonal Gammopathy of Undetermined Significance Successfully Treated with Corticosteroids.

Authors:  Yutaka Tsukamoto; Masataka Umeda; Yuko Muto; Takashi Sugimoto; Momoko Yamauchi; Koji Ando; Koya Ariyoshi
Journal:  Intern Med       Date:  2022-03-26       Impact factor: 1.282

3.  Severe warm autoimmune hemolytic anemia in COVID-19 managed with least incompatible RBC product and glucocorticoids.

Authors:  Tien-Chan Hsieh; Oleg Sostin
Journal:  Ann Hematol       Date:  2021-02-18       Impact factor: 3.673

4.  The JANUS of chronic inflammatory and autoimmune diseases onset during COVID-19 - A systematic review of the literature.

Authors:  Lucia Novelli; Francesca Motta; Maria De Santis; Aftab A Ansari; M Eric Gershwin; Carlo Selmi
Journal:  J Autoimmun       Date:  2020-12-14       Impact factor: 7.094

5.  Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review.

Authors:  Kuo-Tung Tang; Bo-Chueh Hsu; Der-Yuan Chen
Journal:  Front Immunol       Date:  2021-03-12       Impact factor: 7.561

Review 6.  Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature.

Authors:  Bruno Fattizzo; Raffaella Pasquale; Valentina Bellani; Wilma Barcellini; Austin G Kulasekararaj
Journal:  Front Immunol       Date:  2021-11-25       Impact factor: 7.561

7.  An association between a positive direct antiglobulin test and HLA-DR12 in COVID-19.

Authors:  Hideaki Matsuura; Sumie Fujii; Yusuke Matsui; Yukari Sugiura; Hidehiko Akiyama; Yasuo Miura
Journal:  Ann Hematol       Date:  2022-07-14       Impact factor: 4.030

8.  Positive Direct Antiglobulin Test in COVID-19 patients: decision-making process.

Authors:  Julien Cabo; Alice Brochier; Pascale Saussoy; Marie-Astrid van Dievoet; Lena Capirchio; Bénédicte Delire; Véronique Deneys
Journal:  Transfus Clin Biol       Date:  2021-06-07       Impact factor: 1.406

9.  [Influence of COVID-19 on the occurrence and treatment of hemolytic diseases].

Authors:  Z Wang; Y P Zhao
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-10-14
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.